Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10045381HBVENSG00000065243.20protein_codingPKN2NoNo5586Q16513
TVIS30001575HIVENSG00000065243.20protein_codingPKN2NoNo5586Q16513
TVIS30024272HIVENSG00000065243.20protein_codingPKN2NoNo5586Q16513
TVIS30024273HIVENSG00000065243.20protein_codingPKN2NoNo5586Q16513
TVIS30024274HIVENSG00000065243.20protein_codingPKN2NoNo5586Q16513
TVIS30024275HIVENSG00000065243.20protein_codingPKN2NoNo5586Q16513
TVIS30024276HIVENSG00000065243.20protein_codingPKN2NoNo5586Q16513
TVIS30024277HIVENSG00000065243.20protein_codingPKN2NoNo5586Q16513
TVIS30024278HIVENSG00000065243.20protein_codingPKN2NoNo5586Q16513
TVIS30024279HIVENSG00000065243.20protein_codingPKN2NoNo5586Q16513
TCGA Plot Options
Drug Information
GenePKN2
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0009521
UniProt IDQ16513
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830